Arrowpoint Investment Partners’s DexCom DXCM Stock Holding History

Arrowpoint Investment Partners’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-3,628	Closed	-$228K	–	137
2026 Q1	$228K	Buy	+3,628	New	+$253K	0.2%	68
2025 Q2	–	Sell	-23,377	Closed	-$1.6M	–	331
2025 Q1	$1.6M	Buy	+23,377	New	+$1.91M	0.19%	129

Other funds holding DXCM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Arrowpoint Investment Partners's DXCM Position: Q2 2026 in Review

Arrowpoint Investment Partners sold out of DexCom (DXCM) in Q2 2026, closing a stake of 3,628 shares — an estimated $228K sold.

Arrowpoint Investment Partners first reported a position in DXCM in Q1 2025 and held it in 2 quarters. The position peaked at $1.6M in Q1 2025. 971 funds tracked by Wall St. Rank hold DXCM as of Q2 2026.

Arrowpoint Investment Partners reported no remaining DexCom position as of Q2 2026 after selling out during the quarter.
Arrowpoint Investment Partners sold 3,628 DexCom shares in Q2 2026, an estimated $228K.
Arrowpoint Investment Partners first reported a position in DexCom in Q1 2025 and held it in 2 quarters.
Arrowpoint Investment Partners's DexCom position peaked at $1.6M in Q1 2025.
971 funds tracked by Wall St. Rank held DexCom as of Q2 2026.

Based on Arrowpoint Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.